Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle.

In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently approved type of antibody, including the clinical data. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index. Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.

Comprehensive reference source for the development, production and therapeutic application of antibodies. Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. Volume III features detailed and specific information about each currently approved type of antibody, including the clinical data.

This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes.

This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a competitively priced softcover edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data. Nearly 100 international experts and researchers from academia, industry, and such regulating bodies as the FDA have contributed to this work. Includes are also information on intellectual property issues, hardly available elsewhere. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic. From the foreword by Mark Glassy, Chairman & Professor, The Rajko Medenica Research Foundation, and Chief Executive Officer, Shantha West, Inc., San Diego, CA, USA: "After more than a century of intense analysis, antibodies continue to amaze and inspire. This Handbook of Therapeutic Antibodies is not just an assembly of articles but rather a state-of-the-art comprehensive compendium, which will appeal to all those interested in antibodies, whether from academia, industry, or the clinic. It is an unrivalled resource which shows how mature the antibody field has become and how precisely the antibody molecule can be manipulated and utilized." Stefan Dubel studied biology at the universities of Mainz and Heidelberg, initially concentrating on developmental biology. From 1989 onwards he carried out pioneering work on antibody phage display and antibody libraries with randomised CDRs. Further work focussed on antibody fusion proteins and improvements of antibody phage display. Currently he is Director of the Department of Biotechnology at the Technical University of Braunschweig and coordinator of the 'Antibody Factory' within the German National Genome Research Network. Stefan Dubel has co-authored a number of textbooks, about 90 publications and 15 patents in the field of recombinant antibodies and phage display.